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Abstract
Context—Human immunodeficiency virus (HIV) infection complicates care and contributes to 
poor outcomes among tuberculosis (TB) patients. The Centers for Disease Control and Prevention 
recommends that providers test all TB patients for HIV.
Objective—We assessed completeness of HIV status determination among TB patients and 
identified key gaps in adherence.
Design—We conducted a retrospective review of public health charts to determine the HIV 
status for all TB patients reported in California during 2008. We then used logistic regression to 
determine the factors associated with a known (positive or negative) HIV status. A random sample 
of TB patients was selected for secondary review to characterize the timing of HIV status 
determination and the providers who had opportunity to test for HIV.
Setting—California TB programs.
Participants—All TB patients reported from California in 2008.
Main Outcome Measures—Proportion of patients with a known HIV status, adjusted odds 
ratios for having a known HIV status, proportion of patients with a known HIV status before TB 
diagnosis, and proportion of patients diagnosed with TB by different provider types.
Results—Only 1752 (66%) of 2667 TB patients had a known HIV status. Having a known HIV 
status was strongly associated with those aged between 15 and 44 years and being managed with 
any public provider involvement. Of 292 patients in the random sample, 12 patients (4%) had a 
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known HIV status before TB diagnosis. Among the remaining 280 patients, 187 patients (67%) 
were diagnosed with TB by a private provider.
Conclusions—The HIV status determination of TB patients was selective and not routine as 
recommended. Private providers can play a key role in testing for HIV at TB diagnosis. California 
TB programs should ensure that all TB patients have an HIV status by promulgating national 
recommendations, educating private providers on the benefits of testing TB patients for HIV, and 
monitoring completeness of HIV status determination.
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Since 1989, the Centers for Disease Control and Prevention (CDC) has recommended 
testing all tuberculosis (TB) patients for human immunodeficiency virus (HIV).1,2 
Beginning in 2006, the CDC recommended routine provider-initiated opt-out HIV testing 
for all patients in health care settings.3 The United States has made progress toward the 
national standard of routine HIV testing as the percentage of TB patients with a known 
(positive or negative) HIV status increased from 35% in 1993 to 80% in 2008.4 Data from 
California have not been included in these national estimates because HIV status of TB 
patients only recently became reportable to the state. This is a major gap for determining 
national trends because California reports the greatest number of TB patients of any state.
This also presents a gap in TB management and public health TB control. Human 
immunodeficiency virus infection is a risk factor for death with TB,5-9 TB recurrence,10 and 
acquired TB drug resistance with intermittent therapy.11-13 Thus, HIV status determination 
is needed to identify TB patients who should receive daily directly observed TB therapy and 
highly active antiretroviral therapy to prevent poor TB outcomes.14-17 Human 
immunodeficiency virus status determination is also needed for TB programs to link HIV-
infected TB patients to HIV care services and to identify HIV-infected contacts, who are at 
increased risk for progression to disease.18
Ensuring complete HIV status determination among patients is part of TB programs’ 
broader responsibility to monitor and ensure the quality of all TB-related activities. 
However, the decision to test patients for HIV ultimately rests with the provider. Although 
TB programs can directly implement routine HIV testing for patients in public TB clinics, 
they have less influence over the care given by private providers. Therefore, public health 
efforts to ensure complete HIV status determination must consider the provider types 
involved in TB care and target interventions appropriately.
We conducted an evaluation of TB patients reported from California in 2008 to (1) assess 
completeness of HIV status determination, (2) identify factors associated with having a 
known HIV status, (3) characterize providers who have opportunity to test for HIV during 
TB care, and (4) provide recommendations to increase HIV status determination 
completeness.
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Data sources and evaluation design
There are 58 county and 3 city TB programs in California responsible for receiving TB case 
reports and maintaining public health records to monitor treatment for all TB patients. If 
patients are managed directly by TB programs, public health records are compiled from 
public TB clinic records. If patients are managed by private providers, private providers 
provide documentation for public health records. Because TB treatment and follow-up can 
last more than 1 year, patients reported in 2008 had the most complete data at the time of our 
evaluation.
We abstracted HIV status from public health records for all TB patients reported from 
California in 2008 and linked these data to individual demographic and clinical data from 
the state TB registry. From this data set, we assessed completeness of HIV status 
determination and identified factors associated with having a known HIV status.
We also selected a simple random sample of 300 TB patients from jurisdictions reporting at 
least 5 TB patients in 2008 for secondary public health record review. This secondary 
review was done to verify HIV status documentation, to assess timing of HIV status 
determination, and to characterize the type of provider at specific stages of TB care. This 
evaluation was reviewed and approved by the California Health and Human Services 
Agency institutional review board and all relevant county review boards.
Definitions
Negative HIV status was defined as having one of the following before TB treatment 
completion but no earlier than a year before TB diagnosis: (1) a negative test result or (2) 
documentation of a negative HIV status from a previous or referring clinician. Positive HIV 
status was defined as having one of the following before TB treatment completion: (1) a 
positive test result, (2) a report of highly active antiretroviral therapy medication, (3) 
documentation of HIV diagnosis from a previous or referring clinician, or (4) self-report of 
positive HIV status. A known HIV status was defined as having a positive or negative HIV 
status with all others having an unknown HIV status. The TB diagnosis date was the earliest 
of the report date, collection date of the first positive sputum culture, or the TB treatment 
start date.
Individual demographic and clinical data from the state TB registry conformed to the 
requirements for the national TB case report form.19 To identify those patients managed 
according to the policies and procedures of the TB programs, patients were categorized as 
either managed with any public provider involvement or managed solely by private 
providers. Public providers were defined as those who were part of or directed by TB 
programs. All other providers, including some county hospital clinicians not associated with 
TB programs, were classified as private providers.
We characterized the timing of HIV status determination in relation to the TB diagnosis 
date. Because the time from initial health visit to TB confirmation might be longer than 2 
months, the 3 months before TB diagnosis were considered to be the TB diagnostic period. 
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Patients without a known HIV status documented before the TB diagnostic period were 
considered to have no previously known HIV status. Patients who did not have a previously 
known HIV status but had subsequent documentation of HIV status were considered to have 
a newly identified HIV status. For patients with a newly identified HIV status and a 
documented HIV test, the time to test was calculated as the number of days from the TB 
diagnosis date to the HIV specimen collection date. Negative values indicated that HIV 
specimen collection preceded the TB diagnosis date. Patients without a precise HIV 
specimen collection date were excluded from analysis of the time to test.
Statistical analysis
Analysis was conducted using SAS 9.2 (SAS Institute, Cary, North Carolina). We calculated 
proportions of patients with a known HIV status and with HIV infection grouped by clinical 
and demographic characteristics. Because HIV testing is recommended early in TB 
treatment, we examined patient characteristics apparent on initial TB presentation. These 
characteristics included age, sex, race, birthplace, site of TB disease, previous TB, and 
history of incarceration, homelessness, excess alcohol use, or illicit drug use. We also 
examined patients by type of provider managing TB care. We used logistic regression to 
identify factors associated with having a known HIV status and to calculate odds ratios, 
adjusted odds ratios, and confidence intervals. Factors with P < .05 were considered 
significant. A multivariate logistic model including all patients with a known provider type 
was chosen using backward-stepwise hierarchical selection. We also tested for interaction 
between race and nativity.
We characterized the timing and providers relevant to HIV status determination among the 
patients in our random sample. We calculated the percentage of patients with a previously 
known HIV status and the percentage with a newly identified HIV status. We determined the 
frequency of patients by their provider at TB diagnosis, at TB treatment initiation, and for 
the majority of TB care. We also determined the frequency of patients who ever visited a 
public TB clinic. Among patients who had a newly identified HIV status and a documented 
HIV test, we calculated the percentage of patients whose test was ordered by public 
providers and the time to test. The Wilcoxon-Mann-Whitney test was used to compare the 
distribution of the time to test stratified by ordering provider type.
Results
HIV status determination among patients
Of the 2697 TB patients reported during 2008 in California, 30 (1%) patients had public 
health records unavailable, leaving 2667 (99%) patients for review. Of the 2667 patients 
whose records were reviewed, 132 (5%) patients were HIV positive and 1620 (61%) patients 
were HIV negative summing to 1752 (66%) patients with a known HIV status. The 
remaining 915 (34%) patients had an unknown HIV status. Of these, 164 (18%) patients 
refused an HIV test, 154 (17%) patients were offered a test but did not have locatable 
results, and 597 (65%) patients had no HIV status or test documentation. Patients managed 
solely by private providers comprised 819 of 2667 (31%) TB patients. Only 377 of these 
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819 (46%) patients had a known HIV status compared with 1343 of 1799 (75%) patients 
managed with any public provider involvement (P < .01, Table 1).
Human immunodeficiency virus–infection prevalence was 8% among patients with a known 
HIV status. Human immunodeficiency virus–infection prevalence was associated with age, 
sex, race, birthplace, site of TB disease, and history of incarceration, homelessness, excess 
alcohol use, or illicit drug use (Table 1).
Factors associated with having a known HIV status
Factors associated with having a known HIV status were identified through bivariate and 
multivariate analysis (Table 2). Forty-nine patients were excluded because they had an 
unknown provider type. Among the 2618 patients remaining, 1720 (66%) patients had a 
known HIV status. Provider type, age, sex, previous TB, birthplace, race, and history of 
incarceration, homelessness, excess alcohol use, or illicit drug use were associated with 
having a known HIV status in bivariate analysis.
Statistically significant factors in bivariate analysis remained significant in multivariate 
analysis. Age and provider type were strongly associated with having a known HIV status. 
A known HIV status was less likely among females but was more likely among patients who 
had previous TB. History of incarceration, homelessness, excess alcohol use, or illicit drug 
use was also associated with having a known HIV status, but only if the patient had a history 
of at least 2 behaviors.
Interaction between race and birthplace was detected. Among foreign-born patients, Asians 
and Hispanics were more likely to have a known HIV status than whites. However, among 
US-born patients, Asians and Hispanics were less likely to have a known HIV status.
Timing of HIV status determination
A random sample of 300 patients was selected for secondary record review to ascertain the 
timing of HIV status determination. Records were unavailable for 3 patients. Of the 
remaining 297 patients, 5 (2%) patients were dead at diagnosis and had no HIV status 
documented (the Figure). Of the 292 patients alive at TB diagnosis, 280 (96%) patients did 
not have a previously known HIV status (an HIV status determined more than 3 months 
before the TB diagnosis date). Of the 280 patients who did not have a previously known 
HIV status, 171 (61%) patients had a newly identified HIV status and a documented HIV 
test, 7 (3%) patients had no documented HIV test but had documentation of a negative HIV 
status from a referring clinician, and 102 (36%) patients had no documentation of an HIV 
test or HIV status. Of the 171 patients who had a newly identified HIV status from testing, 
164 (96%) patients were HIV negative and 7 (4%) patients were HIV positive. Overall, of 
the 297 sampled patients, 190 (64%) patients had a known HIV status and 15 (5%) patients 
were HIV positive. Seven of the 15 (47%) HIV-positive patients were not previously known 
to be HIV positive, but were subsequently identified through testing.
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Providers involved with TB treatment and HIV testing
Through secondary review, we characterized the providers at different stages of TB 
treatment for the 280 patients without a previously known HIV status. Of these patients, 187 
(67%) patients were diagnosed with TB exclusively by private providers and 186 (66%) 
patients had the majority of their TB treatment managed by public providers (Table 3). 
Among the 171 patients with the recommended HIV testing, 90 (53%) patients had tests 
ordered by public providers (Table 4). All but 1 of the HIV tests ordered by public providers 
were done in an outpatient setting. In contrast, 51 of the 70 (73%) HIV tests ordered by 
private providers were done in an inpatient setting. The median time from TB diagnosis to 
HIV test was 0 days when HIV tests were ordered by private providers compared with 11 
days when HIV tests were ordered by public providers (P < .01).
Discussion
Only 66% of TB patients reported from California in 2008 had a known HIV status 
documented in public health charts, which was far below the national average of 80%. It is 
concerning that one-third of all TB patients did not have a known HIV status because 
patients with undiagnosed HIV might have missed an opportunity for HIV diagnosis and 
adequate TB treatment. Without adequate treatment, they would be more likely to 
experience poor TB outcomes including death. Such a large proportion of patients with 
missing HIV status information also introduces uncertainty regarding the true burden of HIV 
and TB comorbidity in California and impacts national estimates of HIV and TB 
comorbidity. We found an HIV-infection prevalence of 8% among those with a known HIV 
status, but the true prevalence among all TB patients is unknown. To ensure that all HIV-
infected TB patients are identified, California must improve HIV status determination 
efforts.
Human immunodeficiency virus status determination was not uniformly low across all 
patient groups. Groups that were less likely to have a known HIV status were also those 
groups with a lower HIV-infection prevalence. Age was most strongly associated with 
having a known HIV status. Those younger than 15 years and those older than 45 years were 
less likely to have a known HIV status than those aged between 30 and 44 years. Females, 
US-born Asians, and patients without previous TB were also less likely to have a known 
HIV status. Patients without a history of incarceration, homelessness, excess alcohol use, or 
illicit drug use were less likely to have a known HIV status than those with a history of 2 or 
more behaviors. This suggests that HIV status determination was driven by provider-
perceived risk for HIV infection and was not routine as recommended by the CDC. Other 
studies of TB programs have reported similar findings.20-22
However, risk-based testing does not effectively identify all HIV infection because 
clinicians cannot easily identify those at risk.1,3,23 Providers who practice risk-based testing 
might miss HIV infection among female, foreign-born, or older patients, who are 
increasingly represented among HIV-infected TB patients.24,25 Although this evaluation 
detected no or little HIV infection among patients younger than 15 years and patients older 
than 60 years, infection in these groups does occur. Nationally in 2005, HIV infection was 
detected in 1% of TB patients younger than 4 years, in 2% of those aged 5 to 14 years, and 
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in 1% of those older than 64 years.4 Human immunodeficiency virus infection is life 
threatening and should be identified early in any TB patient. Opt-out HIV testing as 
recommended by the CDC, rather than risk-based testing, is necessary to achieve complete 
HIV status determination.26 It also increases patient and provider acceptability of HIV 
testing27,28 and improves linkage to antiretroviral treatment for HIV-infected patients.29 
Finally, HIV testing is cost-effective compared with no testing when the HIV-infection 
prevalence is at least 1.0 per 1000 persons screened, as it was in our population of TB 
patients.30
Provider type was also an important factor in HIV status determination. Less than half of 
patients managed solely by private providers had a known HIV status and being managed 
with any public provider involvement was strongly associated with having a known HIV 
status. This finding warrants further attention because 31% of all TB patients were managed 
solely by private providers and HIV-infection prevalence was 11% among such patients who 
had a known HIV status.
Human immunodeficiency virus testing at TB diagnosis was effective in identifying HIV 
infection. In our random sample, 96% of patients did not have a known HIV status prior to 
the TB diagnostic period. Of note, 4% of those tested were HIV positive. Furthermore, 
almost half of all HIV-positive patients in our sample were not previously known to be HIV 
positive. Although our random sample examined only 15 of the total HIV-positive patients, 
similar findings have been reported by other studies.20,31
Private providers were best positioned to determine HIV status at TB diagnosis because they 
were the provider at TB diagnosis for 67% of patients. Their prominent role in initial TB 
care also explained why private providers ordered HIV tests earlier than public providers. 
Also, most HIV tests ordered by private providers were done in inpatient settings suggesting 
that many patients receive initial TB care in hospitals. Public provider testing is still 
important to achieve complete HIV status determination because many privately diagnosed 
patients were transferred to public care. Although it is possible that private providers do not 
report HIV status to TB programs, TB programs should follow up with private providers or 
the patient to document HIV status in public health records so it can inform care referral.
Tuberculosis providers, especially private providers in inpatient settings, should be engaged 
as partners to address incomplete HIV status determination. Patient acceptability of routine 
HIV tests is higher when providers encourage HIV tests and believe HIV testing benefits the 
patient.28,32-34 Provider education about their role in HIV status determination and 
associated patient benefits should accompany implementation of routine opt-out HIV 
testing.
This was the first statewide evaluation of HIV status determination among TB patients in 
California and included 99% of all TB patients reported in 2008. Nevertheless, this 
evaluation has limitations. Our evaluation included TB patients reported in 2008 only. 
Estimates of HIV-infection prevalence and HIV status determination among specific patient 
groups may have subsequently changed. Also, it was unclear whether patients lacked a 
known HIV status because they were not tested or because their test results were not 
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documented. Because our data sources were public health records maintained by TB 
programs, patients managed solely by private providers were more likely to have incomplete 
HIV status information. If private providers tested for HIV among TB patients but did not 
report results to TB programs, it would cause us to underestimate the percentage of patients 
who have a known HIV status and overestimate the association between provider type and 
having a known HIV status. Regardless, TB programs use public health records to ensure 
adequate management for all TB patients. Therefore, our recommendations for TB programs 
to educate and follow up with private providers still apply irrespective of the reason for not 
documenting HIV status in the public health record. Education efforts could be improved by 
surveying private providers and determining whether HIV tests are not performed or test 
results are simply not reported.
Finally, our evaluation focused on how patient and provider characteristics affect HIV status 
determination. However other factors such as confidentiality concerns, language difficulties, 
test cost, and stigma influence whether HIV tests are offered and accepted. Further research 
is needed to determine whether HIV status determination is low because providers decline to 
offer HIV tests or because TB patients refuse HIV tests. Studies should also identify patient 
and provider concerns regarding HIV testing during TB care and evaluate methods to 
mitigate them. This information would allow TB programs to target specific HIV testing 
barriers among patients and providers.
Despite these limitations, our evaluation completed its objectives by finding that (1) one-
third of California TB patients in 2008 did not have a known HIV status, (2) HIV status 
determination appeared to be selective based on provider-perceived risk, and (3) private 
providers usually have the first opportunity to establish HIV status in TB patients, but 
patients managed solely by private providers were less likely to have a known HIV status. 
To ensure that all HIV-infected TB patients are detected and receive potentially life-saving 
treatment, TB programs should document HIV status for every TB patient as recommended. 
Providers, especially private providers, should also be encouraged to implement routine opt-
out HIV testing for TB patients. On the basis of these recommendations, the California 
Department of Public Health began initiatives targeting TB programs and providers. First, 
we developed and distributed statewide guidelines to TB programs reflecting the CDC 
recommendations for routine optout HIV testing. Second, we produced an information sheet 
explaining the rationale and benefits of routine HIV testing to educate private providers. 
Finally, we established HIV status determination completeness as a statewide performance 
measure and began providing real-time feedback of performance to TB programs.
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FIGURE. Timing of HIV Status Determination for Randomly Sampled Patientsa
aHuman immunodeficiency virus status known 3 months before TB diagnosis is a previously 
known HIV status. The 7 HIV-negative patients who did not have a documented HIV test 
result in the public health chart had documentation of HIV-negative status from a referring 
clinician after TB diagnosis. HIV indicates human immunodeficiency virus; TB, 
tuberculosis.
Kong et al. Page 11

























Kong et al. Page 12
TABLE 1
Characteristics and HIV status of 2667 TB patients, California, 2008







With a Known Status
Total patients 2667 1752 65.7 132 4.9 7.5
Provider type
 Any public provider involvement 1799 1343 74.7 89 4.9 6.6
 Solely by private providers 819 377 46.0 40 4.9 10.6
 Unknown 49 32 65.3 3 6.1 9.4
Age, y
a
 ≤14 155 52 33.5 0 0.0 0.0
 15-29 490 395 80.6 20 4.1 5.1
 30-44 587 452 77.0 70 11.9 15.5
 45-59 626 447 71.4 36 5.8 8.1
 ≤60 809 406 50.2 6 0.7 1.5
Sex
a
 Male 1635 1109 67.8 110 6.7 9.9
 Female 1032 643 62.3 22 2.1 3.4
Previous TB
 No 2534 1652 65.2 125 4.9 7.6
 Yes 133 100 75.2 7 5.3 7.0
History of homelessness, incarceration,
 illicit drug use, or alcohol use
a
 No history of behaviors 2239 1410 63.0 80 3.6 5.7
 History of 1 behavior 239 182 76.2 27 11.3 14.8
 History of 2 or more behaviors 189 160 84.7 25 13.2 15.6
Site of disease
a
 Pulmonary only 1908 1263 66.2 72 3.8 5.7
 Extrapulmonary 759 489 64.4 60 7.9 12.3
Race
a
 White 255 160 62.7 17 6.7 10.6
 Black 209 152 72.7 27 12.9 17.8
 Hispanic 1046 746 71.3 77 7.4 10.3
 Asian 1148 687 59.8 10 0.9 1.5
 AI or NA 8 7 87.5 1 12.5 14.3
 Unknown 1 0 0.0 0 0.0
Birthplace
a
 US-born 654 402 61.5 51 7.8 12.7
 Foreign-born 2013 1350 67.1 81 4.0 6.0
Birthplace and race
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With a Known Status
 US-born
  White 193 125 64.8 17 8.8 13.6
  Black 155 111 71.6 21 13.5 18.9
  Hispanic 244 137 56.1 12 4.9 8.8
  Asian 55 23 41.8 0 0.0 0.0
  AI or NA 7 6 85.7 1 14.3 16.7
 Foreign-born
  White 62 35 56.5 0 0.0 0.0
  Black 54 41 75.9 6 11.1 14.6
  Hispanic 802 609 75.9 65 8.1 10.7
  Asian 1093 664 60.8 10 0.9 1.5
  AI or NA 1 1 100.0 0 0.0 0.0
  Unknown 1 0 0.0 0 0.0
Abbreviations: AI or NA, American Indian or Native Alaskan; HIV, human immunodeficiency virus; TB, tuberculosis.
a
Characteristic is associated with HIV-infection prevalence in bivariate analysis.
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TABLE 2
Bivariate and Multivariate Analysis of Factors Associated With Having a Known HIV Status for 2618 TB 
Patients, California, 2008
a
No. Patients OR (95% CI) P AOR (95% CI) P
Provider type
 Any public provider involvement 1799 Reference Reference
 Solely by private providers 819 0.29 (0.24-0.35) <0.01 0.28 (0.23-0.34) <0.01
Age, y
 ≤14 154 0.15 (0.10-0.22) <0.01 0.15 (0.10-0.24) <0.01
 15-29 478 1.22 (0.91-1.65) 0.19 1.16 (0.84-1.59) 0.36
 30-44 579 Reference Reference
 45-59 610 0.75 (0.57-0.97) 0.03 0.67 (0.51-0.89) 0.01
 ≥60 797 0.30 (0.23-0.38) <0.01 0.31 (0.24-0.40) <0.01
Sex
 Male 1609 Reference Reference
 Female 1009 0.78 (0.66-0.91) <0.01 0.78 (0.65-0.95) 0.01
Previous TB
 No 2488 Reference Reference
 Yes 130 1.57 (1.05-2.35) 0.03 1.72 (1.11-2.67) 0.02
History of homelessness, incarceration,
 illicit drug use, or alcohol use
 No history of behaviors 2201 Reference Reference
 History of 1 behavior 232 1.90 (1.38-2.60) <0.01 1.27 (0.89-1.80) 0.19
 History of 2 or more behaviors 185 3.45 (2.27-5.23) <0.01 1.87 (1.18-2.96) 0.01
Site of disease
 Pulmonary only 1877 Reference
 Extrapulmonary 741 1.19 (0.90-1.57) 0.23
Race
 White 255 Reference
 Black 209 1.58 (1.07-2.35) 0.02
 Hispanic 1024 1.47 (1.10-1.96) 0.01
 Asian 1122 0.89 (0.67-1.17) 0.40
 AI or NA 8 4.15 (0.50-34.28) 0.19
Birthplace
 US-born 648 Reference
 Foreign-born 1970 1.28 (1.07-1.54) 0.01
Birthplace and race
 US-born
  White 193 Reference
  Black 155 0.92 (0.56-1.53) 0.75
  Hispanic 239 0.70 (0.44-1.12) 0.13
  Asian 54 0.45 (0.22-0.91) 0.03
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No. Patients OR (95% CI) P AOR (95% CI) P
  AI or NA 7 1.66 (0.18-15.18) 0.65
 Foreign-born
  White 62 Reference
  Black 54 2.12 (0.88-5.10) 0.09
  Hispanic 785 1.75 (0.98-3.12) 0.06
  Asian 1068 1.28 (0.73-2.26) 0.39





Abbreviations: AI or NA, American Indian or Native Alaskan; AOR, adjusted odds ratios; HIV, human immunodeficiency virus; OR, odds ratios; 
TB, tuberculosis.
a
49 patients did not have a known provider type and were excluded from analysis.
b
Stratum contains a single patient.
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TABLE 3
Providers of TB Care for 280 Sampled Patients Alive at Diagnosis With No Previously Known HIV Status, 
California, 2008
Among Patients Sampled, n (%)
Provider involved with TB diagnosis
 Public 37 (13.2)
 Private 187 (66.8)
 Both 53 (18.9)
 Unknown 3 (1.1)
Provider initiating TB treatment
 Public 103 (36.8)
 Private 172 (61.4)
 Unknown or no treatment 5 (1.8)
Provider for majority of TB treatment
 Public 186 (66.4)
 Private 88 (31.4)
 Unknown or no treatment 6 (2.1)
Ever visited public TB clinic
 Yes 205 (73.2)
 No 74 (26.4)
 Unknown 1 (0.4)
Abbreviations: HIV, human immunodeficiency virus; TB, tuberculosis.
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TABLE 4
Providers and Settings of HIV Tests for 171 Sampled Patients Who Were Tested
Among Patients Tested, n (%)
Provider type
 Public 90 (52.6)
 Private 70 (40.9)
 Unknown 11 (6.4)
Setting
 Inpatient 54 (31.6)
 Outpatient 102 (59.6)
 Unknown 15 (8.8)
Provider type and setting
 Public
  Inpatient 1 (0.6)
  Outpatient 89 (52.0)
  Unknown 0 (0.0)
 Private
  Inpatient 51 (29.8)
  Outpatient 13 (7.6)
  Unknown 6 (3.5)
 Unknown
  Inpatient 2 (1.2)
  Outpatient 0 (0.0)
  Unknown 9 (5.3)
Abbreviation: HIV, human immunodeficiency virus.
J Public Health Manag Pract. Author manuscript; available in PMC 2015 September 08.
